Korea Joongang Daily
Korea JoongAng Daily

LegoChem strikes historic $1.7B license deal with Janssen

Korean biopharmaceutical firm LegoChem Biosciences signed a $1.7 licensing deal with Janssen Biotech for its solid cancer treatment candidate, LCB84, which targets colorectal and gastric cancer tumors.

2023-12-26

Celltrion megamerger to create $9 billion pharma giant

A merger of three listed Celltrion companies will be done by next year to create a pharmaceutical behemoth that logs around 12 trillion won ($8.9 billion) of yearly revenues by 2030, says its founder and chairman Seo Jung-jin.

2023-10-25

Samsung, Sandoz sign deal to commercialize biosimilar SB17

Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

2023-09-11

Celltrion reaches patent agreement for Stelara biosimilar CT-P43

Celltrion reached a patent agreement for its copycat drug of Stelara, a blockbuster psoriasis treatment by Janssen Pharmaceuticals, with Janssen’s parent company Johnson & Johnson (J&J).

2023-08-25

SK plasma to sell Janssen’s anti-cancer treatment Dacogen in Korea

SK plasma will exclusively sell Janssen’s anti-cancer treatment Dacogen in Korea.

2023-02-13

Korea's problem with vaccines is now a glut

With inoculation rates high, Korea is struggling with a surplus of Covid-19 vaccines. Authorities are seeking to extend the shelf life of Pfizer and other vaccines by three months to use them as boosters, and looking for ways to send vaccines...

2022-05-11

Concerns grow as cases remain over 2,000 for 5th day

Korea reported more than 2,000 Covid-19 cases for a fifth consecutive day on Sunday, fueling concerns over a virus resurgence amid the country's return to normalcy.

2021-11-07

3 more groups eligible for Covid-19 booster shots

Korea will give out Covid-19 booster shots to adults in their 50s, patients with underlying diseases and Janssen recipients starting next month.

2021-10-28

Committee will draw roadmap to post-Covid normalcy

The government launched a new government-private sector committee to draw up a roadmap for the post-pandemic transition to normalcy by the end of this month.

2021-10-13

Samsung Bioepis starts Phase 3 trials on SB17

SB17, a Samsung Bioepis biosimilar referencing psoriasis treatment Stelara, is in Phase 3 clinical trials, the company said Tuesday.

2021-07-20